Safety Shot(US:SHOT)2025-11-19 22:01Product Launch and Development - Bonk, Inc. launched the Sure Shot Dietary Supplement in December 2023, aimed at reducing blood alcohol content with 28 active ingredients[174][177]. - Clinical trials for the Sure Shot Dietary Supplement showed a statistically significant reduction in Blood Alcohol Content (BAC) with a p-value of 0.002, demonstrating its efficacy[183][184]. - The Sure Shot Dietary Supplement is manufactured in compliance with Good Manufacturing Practices (GMP) to ensure quality and safety[178]. - The company has conducted extensive informal research since 2010, leading to the development of the Sure Shot Dietary Supplement, with hundreds of pre-clinical tests performed[185]. - The company owns five patents related to the Sure Shot Dietary Supplement, with the most recent patent granted on December 3, 2024, covering the current version of the product[196]. Financial Performance - Beverage sales for the three months ended September 30, 2025, were $1,514,817, a significant increase from $110,213 in the same period in 2024, reflecting a growth of approximately 1,274%[205]. - For the nine months ended September 30, 2025, beverage sales reached $1,601,866, compared to $519,793 in 2024, marking a growth of approximately 208%[213]. - Related party income from digital assets for the three months ended September 30, 2025, was $509,085, compared to no income in the same period in 2024[206]. - Cost of sales for the three months ended September 30, 2025, was $1,480,760, up from $402,399 in 2024, indicating a rise of 268% due to increased revenues[206]. - Cost of sales for the nine months ended September 30, 2025, was $1,522,942, down from $2,549,099 in 2024, reflecting a decrease of 40% due to a one-time inventory write-off in 2024[214]. - Total operating expenses for the three months ended September 30, 2025, were $17,215,566, compared to $11,348,320 in 2024, representing an increase of 52%[207]. - Total operating expenses for the nine months ended September 30, 2025, were $26,990,405, a decrease from $32,923,489 in 2024, indicating a reduction of 18%[215]. - The net loss for the three months ended September 30, 2025, was $33,581,216, compared to a net loss of $11,929,277 in 2024, representing an increase in losses of 182%[205]. Strategic Acquisitions and Investments - The company completed the acquisition of Yerbaé, a premium plant-based energy beverage company, on June 27, 2025, to enhance its presence in the functional beverage market[175][190]. - A Securities Purchase Agreement was entered into on August 8, 2025, for a private investment of $25 million in Series C Convertible Preferred Stock, convertible into approximately 62.7 million shares of common stock[193][194]. - The company is exploring opportunities in the digital asset ecosystem, including a transaction involving Bonk tokens to enhance brand engagement[176][189]. - The company has invested significantly in research and development, acquiring a substantial portfolio of intellectual property to support its innovative product offerings[188]. Regulatory Environment - The company is subject to various U.S. federal, state, and local regulations affecting the production and sale of its dietary supplement and beverages, which could impact its operations[198].